Skip NavigationSkip to Content

Low Plasma Gelsolin Concentrations in Chronic Granulomatous Disease

  1. Author:
    Audley, John
    Gliniewicz, Emily F
    Zarember, Kol A
    Hong, Hanna S
    Wald, Gal
    Kuhns,Doug
    Kang, Elizabeth
    Malech, Harry L
    Suffredini, Anthony F
    Noveck, Robert J
    Dinubile, Mark J
    Levinson, Susan L
    Stossel, Thomas P
    Gallin, John I [ORCID]
  2. Author Address

    Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Neutrophil Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA., Duke Clinical Research Unit, Duke University School of Medicine, Durham, NC, USA., BioAegis Therapeutics, Inc., North Brunswick, NJ, USA., Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. jig@nih.gov.,
    1. Year: 2020
    2. Date: Sep 04
    3. Epub Date: 2020 09 04
  1. Journal: Inflammation
  2. Type of Article: Article
  3. ISSN: 0360-3997
  1. Abstract:

    Plasma gelsolin (pGSN) is the secreted isoform of an intracellular actin remodeling protein found in high concentrations in human plasma. Clinical studies demonstrate reduced pGSN concentrations in several disease states, including severe trauma, burns, and sepsis. Markedly decreased pGSN concentrations in these conditions precede and predict adverse clinical outcomes. In this study, we measured pGSN in patients with chronic granulomatous disease (CGD), a primary immunodeficiency characterized by recurrent infections and dysregulated inflammation. pGSN was quantified using a sandwich ELISA in plasma from healthy volunteers, clinically stable CGD patients, and X-linked CGD carriers and in sera from 12 CGD patients undergoing bone marrow transplantation. pGSN was also quantified in healthy volunteers challenged with intravenous endotoxin. pGSN concentrations were lower in CGD patients without active infection or systemic inflammation compared with healthy control subjects. In CGD patients undergoing bone marrow transplantation, pGSN concentrations increased significantly following successful transplant. X-linked carriers of CGD had normal pGSN. Despite reduction of pGSN in CGD patients, we did not detect significant changes in pGSN over 24 h following challenge of healthy volunteers with intravenous endotoxin (4 ng/kg) that elicited a febrile response. We describe, for the first time, significantly lower pGSN in clinically stable patients with CGD compared with age- and sex-matched healthy volunteers. Low pGSN levels in CGD patients significantly increased following bone marrow transplantation. X-linked carriers of CGD had normal pGSN. In healthy volunteers challenged with intravenous endotoxin, pGSN is not an acute phase reactant.

    See More

External Sources

  1. DOI: 10.1007/s10753-020-01330-w
  2. PMID: 32886268
  3. WOS: 000566065600001
  4. PII : 10.1007/s10753-020-01330-w

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel